ERBB2 and pancreatic neoplasm: Targetable alterations were also identified in IDH1 and PIK3CA. Alterations in FGFR3, ERBB2, AR, and KRAS were recurrently detected in bladder, breast, prostate, and pancreatic cancer, respectively.